Sensei Biotherapeutics Inc Stock Ownership - Who owns Sensei Biotherapeutics?

Insider buying vs selling

Have Sensei Biotherapeutics Inc insiders been buying or selling?
John CelebiPRESIDENT AND CEO2024-02-155,891$0.79
Erin ColganCHIEF FINANCIAL OFFICER2024-02-153,627$0.79
Der Horst Edward VanCHIEF SCIENTIFIC OFFICER2024-02-152,843$0.79
John CelebiPresident and CEO2023-09-11500$0.85
Cambrian Biopharma Inc10% Owner2023-07-311,587,302$1.26
James PeyerDirector2023-07-311,587,302$1.26

1 of 1

SNSE insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when SNSE insiders and whales buy or sell their stock.

SNSE Shareholders

What type of owners hold Sensei Biotherapeutics Inc stock?
James Peyer35.25%8,841,457$6.41MInsider
Hs Investments I LP17.65%4,425,998$3.21MInsider
Cambrian Biopharma Inc14.57%3,653,120$2.65MInsider
Newtyn Management LLC3.71%930,230$674.42kInstitution
Thomas G. Ricks2.73%685,632$497.08kInsider
Vanguard Group Inc2.29%573,844$416.04kInstitution
Renaissance Technologies LLC0.84%211,000$152.98kInstitution
Geode Capital Management LLC0.54%136,318$98.83kInstitution
Bridgeway Capital Management LLC0.45%112,900$81.85kInstitution
John Celebi0.42%105,420$76.43kInsider

1 of 3

SNSE vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
SNSE9.21%71.96%Net Selling
CARA43.18%55.05%Net SellingNet Selling
SYBX5.74%94.26%Net Selling

Sensei Biotherapeutics Stock Ownership FAQ

Who owns Sensei Biotherapeutics?

Sensei Biotherapeutics (NASDAQ: SNSE) is owned by 9.21% institutional shareholders, 71.96% Sensei Biotherapeutics insiders, and 18.83% retail investors. James Peyer is the largest individual Sensei Biotherapeutics shareholder, owning 8.84M shares representing 35.25% of the company. James Peyer's Sensei Biotherapeutics shares are currently valued at $6.34M.

If you're new to stock investing, here's how to buy Sensei Biotherapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.